These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 25860213)

  • 1. Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice.
    Lee IC; Chen YT; Chao Y; Huo TI; Li CP; Su CW; Lin HC; Lee FY; Huang YH
    Medicine (Baltimore); 2015 Apr; 94(14):e688. PubMed ID: 25860213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma.
    Lee PC; Chen YT; Chao Y; Huo TI; Li CP; Su CW; Lee MH; Hou MC; Lee FY; Lin HC; Huang YH
    Liver Int; 2018 Feb; 38(2):321-330. PubMed ID: 28736952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design.
    Reig M; Rimola J; Torres F; Darnell A; Rodriguez-Lope C; Forner A; Llarch N; Ríos J; Ayuso C; Bruix J
    Hepatology; 2013 Dec; 58(6):2023-31. PubMed ID: 23787822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma.
    Wada Y; Takami Y; Tateishi M; Ryu T; Mikagi K; Saitsu H
    PLoS One; 2016; 11(1):e0146456. PubMed ID: 26745625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
    Yada M; Masumoto A; Motomura K; Tajiri H; Morita Y; Suzuki H; Senju T; Koyanagi T
    World J Gastroenterol; 2014 Sep; 20(35):12581-7. PubMed ID: 25253961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.
    Inghilesi AL; Gallori D; Antonuzzo L; Forte P; Tomcikova D; Arena U; Colagrande S; Pradella S; Fani B; Gianni E; Boni L; Laffi G; Di Costanzo F; Marra F
    World J Gastroenterol; 2014 Jan; 20(3):786-94. PubMed ID: 24574751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.
    Wörns MA; Koch S; Niederle IM; Marquardt JU; Nguyen-Tat M; Gamstätter T; Schuchmann M; Schulze-Bergkamen H; Galle PR; Weinmann A
    Dig Liver Dis; 2013 May; 45(5):408-13. PubMed ID: 23182599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
    Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
    J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib continuation after first disease progression could reduce disease flares and provide survival benefits in patients with hepatocellular carcinoma: a pilot retrospective study.
    Fu SR; Zhang YQ; Li Y; Hu BS; He X; Huang JW; Zhan MX; Lu LG; Li JP
    Asian Pac J Cancer Prev; 2014; 15(7):3151-6. PubMed ID: 24815462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.
    Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Tajiri N; Satani M; Niizeki T; Aino H; Okamura S; Iwamoto H; Shimose S; Shirono T; Koga H; Torimura T;
    Cancer Med; 2015 Dec; 4(12):1836-43. PubMed ID: 26471348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use.
    Kuo YH; Wang JH; Hung CH; Rau KM; Wu IP; Chen CH; Kee KM; Hu TH; Lu SN
    J Gastroenterol Hepatol; 2017 Dec; 32(12):1975-1981. PubMed ID: 28295594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study.
    Lee S; Kim BK; Kim SU; Park SY; Kim JK; Lee HW; Park JY; Kim DY; Ahn SH; Tak WY; Kweon YO; Lee JI; Lee KS; Kim HJ; Han KH
    J Gastroenterol Hepatol; 2014; 29(7):1463-9. PubMed ID: 25273508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib.
    Cho HJ; Kim SS; Nam JS; Oh MJ; Kang DR; Kim JK; Lee JH; Kim B; Yang MJ; Hwang JC; Lim SG; Shin SJ; Lee KM; Yoo BM; Lee KJ; Cho SW; Cheong JY
    Cytokine; 2017 Jul; 95():118-125. PubMed ID: 28260649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Factors Associated with Postprogression Survival in Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib Not Eligible for Second-Line Regorafenib Treatment.
    Kuzuya T; Ishigami M; Ishizu Y; Honda T; Hayashi K; Ishikawa T; Nakano I; Hirooka Y; Goto H
    Oncology; 2018; 95(2):91-99. PubMed ID: 29723866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function.
    Yang H; Woo HY; Lee SK; Han JW; Jang B; Nam HC; Lee HL; Lee SW; Song DS; Song MJ; Oh JS; Chun HJ; Jang JW; Lozada A; Bae SH; Choi JY; Yoon SK
    Clin Mol Hepatol; 2017 Jun; 23(2):128-137. PubMed ID: 28494528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis.
    Pressiani T; Boni C; Rimassa L; Labianca R; Fagiuoli S; Salvagni S; Ferrari D; Cortesi E; Porta C; Mucciarini C; Latini L; Carnaghi C; Banzi M; Fanello S; De Giorgio M; Lutman FR; Torzilli G; Tommasini MA; Ceriani R; Covini G; Tronconi MC; Giordano L; Locopo N; Naimo S; Santoro A
    Ann Oncol; 2013 Feb; 24(2):406-411. PubMed ID: 23041587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib.
    Yoo JJ; Chung GE; Lee JH; Nam JY; Chang Y; Lee JM; Lee DH; Kim HY; Cho EJ; Yu SJ; Kim YJ; Yoon JH;
    Cancer Res Treat; 2018 Apr; 50(2):366-373. PubMed ID: 28521494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.
    Cho Y; Lee JH; Lee DH; Cho EJ; Yu SJ; Yi NJ; Lee KW; Kim YJ; Yoon JH; Suh KS
    Oncotarget; 2017 Jul; 8(29):47555-47564. PubMed ID: 28548930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib for the Treatment of Advanced Hepatocellular Cancer - a UK Audit.
    King J; Palmer DH; Johnson P; Ross P; Hubner RA; Sumpter K; Darby S; Braconi C; Iwuji C; Swinson D; Collins P; Patel K; Nobes J; Muazzam I; Blesing C; Kirkwood A; Nash S; Meyer T
    Clin Oncol (R Coll Radiol); 2017 Apr; 29(4):256-262. PubMed ID: 27964898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.